News and Comments

THREE SMALL BIOTECH FIRMS IN THE SPOTLIGHT

  Wednesday, July 31, 2013

Three biotechnology firms with market caps below $1billion have been recently put in the spotlight; SYNTA (SNTA) with a market cap of 535.54 million, ARRAY (ARRY) with a market cap of 774.22 million, and VANDA (VNDA) with a market cap of 320.45 million. More...

PERRIGO ACQUIRES ELAN

  Monday, July 29, 2013

Elan is Taken over by Perrigo in a transaction that involves cash and shares of Perrigo.  For the details of the transaction, the press release and the PDF presentation by the New Perrigo Prohost subscribers can click on TODAY'S HIGHLIGHTS at this Website.  More...

ILLUMINA AND THE FUTURE OF LIFE SCIENCES

  Wednesday, July 24, 2013

The moment some investors learned that ILLUMINA (ILMN) might acquire Advanced Liquid Logic (ALL), they debated selling the stock without knowing anything about the acquired firm or the advantages Illumina will add to its technological capability by acquiring it. Is this not the rule of thumb made possible by the power of computers’ programing? ILMN was already down anyway for the day, losing $0.95 during the bad NASDAQ day for the biotech sector in general. Long-term serious investors who are lured to sell ILMN must have felt bad when they heard the news after the end of Monday trading day.     More...

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM

  Thursday, July 11, 2013

A GREAT DAY AND A GREAT FUTURE FOR ALNYLAM  More...

UNREASONABLE CAUSE FOR SELLING CYTK

  Monday, July 08, 2013

The BENEFIT-ALS TRIALS: Cytokinetics (CYTK) announced an update on the conduct of BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS).  The BENEFIT-ALS is a Phase 2b, multinational, double-blind, randomized, placebo-controlled clinical trial designed to evaluate the safety, tolerability and potential efficacy of tirasemtiv, a fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis (ALS). More...


Recent Postings


Archive


Tags

Roche (RHHBY) Galena (GALE) ImmunoGen (IMGN) KERYX (KERX) Human Genome Sciences (HGSI) Pluristem (PSTI) Agenus (AGEN) C4 Therapeutics TOKAI (TKAOI) Ariad (ARIA) Prosensa (RNA) BIOMARIN (BMRN) Gilead (GILD) Micromet (MITI) Theravance Bio Pharma (TBPH) Biocryst (BCRX) Inovio (INO) Human Longevity (HLI) SYNTA (SNTA) Ziofpharm (ZIOP) NEKTAR (NKTR)) ABBVIE (ABBV) Vertex (VRTX) Sarepta (SRPT) Sanofi (SNY) Alnylam (ALNY) GUARDIAN HEALTH NANTKWEST (NK) OSI (OSIP) Herceptin Velcade (bortezomib) Intercept (ICPT) GlaxoSmithKline (GSK) Tysabri IDERA (IDRA) Benlysta (belimumab) Multiple Myeloma ISIS (ISIS) Revlimid (lenolidamide) Auspex (ASPX) Zerenex ACADIA (ACAD) Intrexon (XON) Anadys (ANDS) Rapamune Elan (ELN) Dynavax (DVAX) ARCA (ABIO) Sangamo (SGMO) REGULUS (RGLS) Editas (EDIT) CompuGen (CGEN) Genentech Sanofi-Aventis (SAN) galapagos (GLPG) Valeant Pharmaceuticals International (VRX) PTC Therapeutics (PTCT) Agenus (AGEN Trastuzumab-DM1 Illumina (ILMN) Telaprevir Sequenom (SQNM) VANDA (VNDA) Incyte (INCY) Biogen Idec (BIIB) Vitae Pharmaceuticals (VTAE) Ridaforolimus Bristol-Myers Squibb (BMY) Roche (ROCHE) Regeneron (REGN) Merck (MRK) Jazz Pharmaceuticals (JAZZ) RenenxBio (RGNX) Onyx (ONXX) Theravance (THRX) Aimmune Therapeutics (AIMT) HALOZYME (HALO) Dendreon (DNDN) Prolor Biotech (PBTH) Sanofi (SNA) KITE (KITE) SERES THERAPEUTICS (MCRB) SUNESIS PHARMACEUTICALS (SNSS) Abbott Laboratories (ABT) AERIE PHARMACEUTICALS Cytokinetics (CYTK) Idenix (IDIX) ADVENTRIX (ANX) Amgen (AMGN) Alder Biopharmaceuticals (ALDR) Xoma (XOMA) ZALTRAP™ Seattle Genetics (SGEN) Intermune (ITMN) JUNO (JUNO) Mirati Therapeutics (MRTX) Exelixis (EXEL) Ionis (IONS) Endometrial Cancer Anacor (ANAC) Array Pharmaceuticals (ARRY)